Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
Warning: file_get_contents(http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=18602922&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 445
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations Senter L; Clendenning M; Sotamaa K; Hampel H; Green J; Potter JD; Lindblom A; Lagerstedt K; Thibodeau SN; Lindor NM; Young J; Winship I; Dowty JG; White DM; Hopper JL; Baglietto L; Jenkins MA; de la Chapelle AGastroenterology 2008[Aug]; 135 (2): 419-28BACKGROUND & AIMS: Although the clinical phenotype of Lynch syndrome (also known as hereditary nonpolyposis colorectal cancer) has been well described, little is known about disease in PMS2 mutation carriers. Now that mutation detection methods can discern mutations in PMS2 from mutations in its pseudogenes, more mutation carriers have been identified. Information about the clinical significance of PMS2 mutations is crucial for appropriate counseling. Here, we report the clinical characteristics of a large series of PMS2 mutation carriers. METHODS: We performed PMS2 mutation analysis using long-range polymerase chain reaction and multiplex ligation-dependent probe amplification for 99 probands diagnosed with Lynch syndrome-associated tumors showing isolated loss of PMS2 by immunohistochemistry. Penetrance was calculated using a modified segregation analysis adjusting for ascertainment. RESULTS: Germ-line PMS2 mutations were detected in 62% of probands (n = 55 monoallelic; 6 biallelic). Among families with monoallelic PMS2 mutations, 65.5% met revised Bethesda guidelines. Compared with the general population, in mutation carriers, the incidence of colorectal cancer was 5.2-fold higher, and the incidence of endometrial cancer was 7.5-fold higher. In North America, this translates to a cumulative cancer risk to age 70 years of 15%-20% for colorectal cancer, 15% for endometrial cancer, and 25%-32% for any Lynch syndrome-associated cancer. No elevated risk for non-Lynch syndrome-associated cancers was observed. CONCLUSIONS: PMS2 mutations contribute significantly to Lynch syndrome, but the penetrance for monoallelic mutation carriers appears to be lower than that for the other mismatch repair genes. Modified counseling and cancer surveillance guidelines for PMS2 mutation carriers are proposed.|*Gene Expression Regulation, Neoplastic[MESH]|*Germ-Line Mutation[MESH]|Adenosine Triphosphatases/analysis/*genetics[MESH]|Adult[MESH]|Aged[MESH]|Colorectal Neoplasms, Hereditary Nonpolyposis/chemistry/*genetics/pathology[MESH]|Colorectal Neoplasms/chemistry/*genetics/pathology[MESH]|DNA Mutational Analysis/methods[MESH]|DNA Repair Enzymes/analysis/*genetics[MESH]|DNA-Binding Proteins/analysis/*genetics[MESH]|Endometrial Neoplasms/chemistry/*genetics/pathology[MESH]|Female[MESH]|Genotype[MESH]|Heterozygote[MESH]|Humans[MESH]|Immunohistochemistry[MESH]|Ligase Chain Reaction[MESH]|Male[MESH]|Middle Aged[MESH]|Mismatch Repair Endonuclease PMS2[MESH]|Odds Ratio[MESH]|Penetrance[MESH]|Phenotype[MESH]|Polymerase Chain Reaction[MESH]|Proto-Oncogene Proteins B-raf/genetics[MESH]|Risk Assessment[MESH] |